You have 9 free searches left this month | to do more

ibrutinib

Ibrutinib is a drug used to treat Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, and other conditions. Ibrutinib is being actively studied in 153 studies and prior, has been studied in 66.

Top SponsorsTop SitesTop Investigators
Pharmacyclics LLC.Ohio State University Comprehensive Cancer CenterJennifer Woyach
National Cancer Institute (NCI)Memorial Sloan Kettering Cancer CenterBrian Jonas
M.D. Anderson Cancer CenterM D Anderson Cancer CenterKerry Rogers
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
M
Recruiting
  • Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
  • +2 more
  • Ibrutinib
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2021-10-29
Oct 29, 2021
M
Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +4 more
  • Daratumumab
  • Ibrutinib
  • Jacksonville, Florida
    Mayo Clinic in Florida
2022-03-22
Mar 22, 2022
M
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • La Jolla, California
    UC San Diego Moores Cancer Center
2021-05-06
May 6, 2021
M
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Ibrutinib
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-15
Mar 15, 2022
M
Active, not recruiting
  • Stage I Chronic Lymphocytic Leukemia
  • +3 more
  • Ibrutinib
  • Laboratory Biomarker Analysis
  • Jacksonville, Florida
    Mayo Clinic in Florida
2022-03-24
Mar 24, 2022
W
Recruiting
  • Prostate Cancer
  • Ibrutinib
  • +2 more
  • San Francisco, California
  • +1 more
2021-12-09
Dec 9, 2021
D
Recruiting
  • Primary Central Nervous System Lymphoma
  • Recurrent Cancer
  • Ibrutinib
  • +2 more
  • Boston, Massachusetts
  • +2 more
2022-03-29
Mar 29, 2022
O
Completed
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Ibrutinib
  • Obinutuzumab
  • Portland, Oregon
    OHSU Knight Cancer Institute
2021-12-10
Dec 10, 2021
M
Completed
  • Lung Cancer
  • Ibrutinib
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2021-09-21
Sep 21, 2021
D
Terminated
  • Chronic Graft-versus-host-disease
  • Lebanon, New Hampshire
    Dartmouth-Hitchcock Medical Center
2021-09-27
Sep 27, 2021
M
Active, not recruiting
  • Prolymphocytic Leukemia
  • +2 more
  • Ibrutinib
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-08
Feb 8, 2022
D
Active, not recruiting
  • Waldenstrom's Macroglobulinemia
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2021-05-26
May 26, 2021
C
Active, not recruiting
  • Recurrent Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Brentuximab Vedotin
  • Ibrutinib
  • Duarte, California
  • +2 more
2022-03-28
Mar 28, 2022
D
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Boston, Massachusetts
  • +3 more
2022-01-03
Jan 3, 2022
B
Recruiting
  • Adult B Acute Lymphoblastic Leukemia
  • Philadelphia Chromosome Positive
  • Blinatumomab
  • Ibrutinib
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
2021-10-11
Oct 11, 2021
B
Completed
  • Myelodysplastic Syndrome
  • +4 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
2021-10-11
Oct 11, 2021
J
Active, not recruiting
  • Aplastic Anemia
  • +6 more
  • Best Practice
  • Ibrutinib
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2022-02-24
Feb 24, 2022
N
Active, not recruiting
  • Recurrent Mantle Cell Lymphoma
  • Ibrutinib
  • +3 more
  • Saint Louis, Missouri
  • +3 more
2022-02-12
Feb 12, 2022
G
Recruiting
  • Refractory Follicular Lymphoma
  • Relapsed Follicular Lymphoma
  • Washington, District of Columbia
  • +2 more
2021-12-14
Dec 14, 2021
M
Recruiting
  • Metastatic Melanoma
  • +6 more
  • Ibrutinib
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
2022-03-11
Mar 11, 2022
N
Completed
  • Diffuse Large B-cell Lymphoma
  • Tisagenlecleucel
  • Ibrutinib
  • Tampa, Florida
  • +1 more
2021-11-18
Nov 18, 2021
A
Withdrawn
  • Asymptomatic COVID-19 Infection Laboratory-Confirmed
  • +8 more
  • Ibrutinib
  • Quality-of-Life Assessment
  • Rochester, Minnesota
    Mayo Clinic in Rochester
2021-12-01
Dec 1, 2021
M
Suspended
  • Recurrent Waldenstrom Macroglobulinemia
  • +2 more
  • Ibrutinib
  • +4 more
  • Jacksonville, Florida
  • +1 more
2021-08-02
Aug 2, 2021
S
Completed
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Duarte, California
  • +1 more
2021-09-01
Sep 1, 2021